1.WHO. Globally Tuberculosis Report 2018. Geneva: World Health Organization; 2018.
2.WHO. WHO treatment guidlines for multidrug- and rifampicin-resistant tuberculosis. Geneva: World Health Organization; 2018.
3.Emily A Kendall, Mariam O Fofana, David W Dowdy. Burden of transmitted multidrug resistance in epidemics of tuberculosis: a transmission modelling analysis. Lancet Respir Med. 2015.
4.Yang C, Shen X, Peng Y, Lan R, Zhao Y, Long B, et al. Transmission of Mycobacterium tuberculosis in China: a population-based molecular epidemiologic study. Clinical infectious diseases: an official publication of the Infectious Diseases Society of America. 2015;61(2):219–27.
5.Dharmadhikari AS, Mphahlele M, Venter K, Stoltz A, Mathebula R, Masotla T, et al. Rapid impact of effective treatment on transmission of multidrug-resistant tuberculosis. The international journal of tuberculosis and lung disease: the official journal of the International Union against Tuberculosis and Lung Disease. 2014;18(9):1019–25.
6.Kurbatova EV, Cegielski JP, Lienhardt C, Akksilp R, Bayona J, Becerra MC, et al. Sputum culture conversion as a prognostic marker for end-of-treatment outcome in patients with multidrug-resistant tuberculosis: a secondary analysis of data from two observational cohort studies. The Lancet Respiratory Medicine. 2015;3(3):201–9.
7.Javaid A, Ahmad N, Afridi AK, Basit A, Khan AH, Ahmad I, et al. Validity of Time to Sputum Culture Conversion to Predict Cure in Patients with Multidrug-Resistant Tuberculosis: A Retrospective Single-Center Study. Am J Trop Med Hyg. 2018;98(6):1629–36.
8.Lu P, Liu Q, Martinez L, Yang H, Lu W, Ding X, et al. Time to sputum culture conversion and treatment outcome of patients with multidrug-resistant tuberculosis: a prospective cohort study from urban China. The European respiratory journal. 2017;49(3).
9.Atif M, Bashir A, Ahmad N, Fatima RK, Saba S, Scahill S. Predictors of unsuccessful interim treatment outcomes of multidrug resistant tuberculosis patients. BMC infectious diseases. 2017;17(1):655.
10.Gadallah MA, Mokhtar A, Rady M, El-Moghazy E, Fawzy M, Kandil SK. Prognostic factors of treatment among patients with multidrug-resistant tuberculosis in Egypt. J Formos Med Assoc. 2016;115(11):997–1003.
11.Yihunie Akalu T, Muchie KF, Alemu Gelaye K. Time to sputum culture conversion and its determinants among Multi-drug resistant Tuberculosis patients at public hospitals of the Amhara Regional State: A multicenter retrospective follow up study. PloS one. 2018;13(6):e0199320.
12.Shibabaw A, Gelaw B, Wang SH, Tessema B. Time to sputum smear and culture conversions in multidrug resistant tuberculosis at University of Gondar Hospital, Northwest Ethiopia. PloS one. 2018;13(6):e0198080.
13.Liu Q, Lu P, Martinez L, Yang H, Lu W, Ding X, et al. Factors affecting time to sputum culture conversion and treatment outcome of patients with multidrug-resistant tuberculosis in China. BMC infectious diseases. 2018;18(1):114.
14.Li Q, Zhao G, Wu L, Lu M, Liu W, Wu Y, et al. Prevalence and patterns of drug resistance among pulmonary tuberculosis patients in Hangzhou, China. Antimicrob Resist Infect Control. 2018;7:61.
15.Huang F, Cheng S, Du X, Chen W, Scano F, Falzon D, et al. Electronic recording and reporting system for tuberculosis in China: experience and opportunities. J Am Med Inform Assoc. 2014;21(5):938–41.
16.World Health Organization. Companion Handbook to the WHO Guidelines for the Programmatic Management of Drug-Resistant Tuberculosis. Geneva2016.
17.Diacon AH, Pym A, Grobusch MP, de los Rios JM, Gotuzzo E, Vasilyeva I, et al. Multidrug-Resistant Tuberculosis and Culture Conversion with Bedaquiline. New England Journal of Medicine. 2014;371(8):723–32.
18.Tierney DB, Franke MF, Becerra MC, Alca´ntara Viru´ FlA, Bonilla CsA, Sa´nchez E. time to culture conversion and regimen composition in MDR treatment. PloS one. 2014;9(9):e10835.
19.Parmar MM, Sachdeva KS, Dewan PK, Rade K, Nair SA, Pant R, et al. Unacceptable treatment outcomes and associated factors among India’s initial cohorts of multidrug-resistant tuberculosis (MDR-TB) patients under the revised national TB control programme (2007–2011): Evidence leading to policy enhancement. PloS one. 2018;13(4):e0193903.
20.Xu C, Pang Y, Li R, Ruan Y, Wang L, Chen M, et al. Clinical outcome of multidrug-resistant tuberculosis patients receiving standardized second-line treatment regimen in China. The Journal of infection. 2018;76(4):348–53.
21.Alene KA, Yi H, Viney K, McBryde ES, Yang K, Bai L, et al. Treatment outcomes of patients with multidrug-resistant and extensively drug resistant tuberculosis in Hunan Province, China. BMC infectious diseases. 2017;17(1):573.
22.Lv L, Li T, Xu K, Shi P, He B, Kong W, et al. Sputum bacteriology conversion and treatment outcome of patients with multidrug-resistant tuberculosis. Infect Drug Resist. 2018;11:147–54.
23.van Altena R, de Vries G, Haar CH, de Lange WC, Magis-Escurra C, van den Hof S, et al. Highly successful treatment outcome of multidrug-resistant tuberculosis in the Netherlands, 2000–2009. The international journal of tuberculosis and lung disease: the official journal of the International Union against Tuberculosis and Lung Disease. 2015;19(4):406–12.
24.Trebucq A, Schwoebel V, Kashongwe Z, Bakayoko A, Kuaban C, Noeske J, et al. Treatment outcome with a short multidrug-resistant tuberculosis regimen in nine African countries. The international journal of tuberculosis and lung disease: the official journal of the International Union against Tuberculosis and Lung Disease. 2018;22(1):17–25.
25.Velayutham B, Nair D, Kannan T, Padmapriyadarsini C, Sachdeva KS, Bency J, et al. Factors associated with sputum culture conversion in multidrug-resistant pulmonary tuberculosis. The International Journal of Tuberculosis and Lung Disease. 2016;20(12):1671–6.
26.Alene KA, Viney K, Yi H, McBryde ES, Yang K, Bai L, et al. Comparison of the validity of smear and culture conversion as a prognostic marker of treatment outcome in patients with multidrug-resistant tuberculosis. PloS one. 2018;13(5):e0197880.
27.Ahmad N, Javaid A, Basit A, Afridi AK, Khan MA, Ahmad I, et al. Management and treatment outcomes of MDR-TB: results from a setting with high rates of drug resistance. The international journal of tuberculosis and lung disease: the official journal of the International Union against Tuberculosis and Lung Disease. 2015;19(9):1109–14, i-ii.
28.Zhang L, Meng Q, Chen S, Zhang M, Chen B, Wu B, et al. Treatment outcomes of multidrug-resistant tuberculosis patients in Zhejiang, China, 2009–2013. Clinical microbiology and infection: the official publication of the European Society of Clinical Microbiology and Infectious Diseases. 2018;24(4):381–8.
29.Yin J, Wang X, Zhou L, Wei X. The relationship between social support, treatment interruption and treatment outcome in patients with multidrug-resistant tuberculosis in China: a mixed-methods study. Trop Med Int Health. 2018;23(6):668–77.
30.Chinese Antituberculosis Association. Guidelines for chemotherapy of drug-resistance tuberculosis(2009). Chin J Tuber Respir Dis. 2010;33(7):485–97.